CAPTRUST Financial Advisors
KPRX icon

CAPTRUST Financial Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,889
Closed -$56.5K – 2229
2024
Q1 		$56.5K Hold
8,889
– – ﹤0.01% 2081
2023
Q4 		$41.8K Hold
8,889
– – ﹤0.01% 2601
2023
Q3 		$45.4K Buy
8,889
+6,667
+300% +$34.1K ﹤0.01% 2488
2023
Q2 		$12.9K Buy
+2,222
New +$46.6K ﹤0.01% 2479
2022
Q3 		– Sell
-42
Closed -$7K – 3118
2022
Q2 		$7K Buy
+42
New +$7.03K ﹤0.01% 3927

Other funds holding KPRX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors's KPRX Position: Q2 2024 in Review

CAPTRUST Financial Advisors sold out of Kiora Pharmaceuticals (KPRX) in Q2 2024, closing a stake of 8,889 shares — an estimated $56.5K sold.

CAPTRUST Financial Advisors first reported a position in KPRX in Q2 2022 and held it in 5 quarters. The position peaked at $56.5K in Q1 2024. 17 funds tracked by Wall St. Rank hold KPRX as of Q2 2024.

  • CAPTRUST Financial Advisors reported no remaining Kiora Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 8,889 Kiora Pharmaceuticals shares in Q2 2024, an estimated $56.5K.
  • CAPTRUST Financial Advisors first reported a position in Kiora Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Kiora Pharmaceuticals position peaked at $56.5K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.